key: cord-0682217-x9nzn1ri
authors: Noticewala, Sonal S.; Ludmir, Ethan B.; Li, Jing; McAleer, Mary Frances
title: In Reply to Rathod et al
date: 2020-08-03
journal: Adv Radiat Oncol
DOI: 10.1016/j.adro.2020.06.009
sha: 9aa0f76f8d7523c1e7005a731b17dba7be9c5701
doc_id: 682217
cord_uid: x9nzn1ri

nan

To the Editor:

We thank Rathod and colleagues for their insightful reply 1 to our article "Radiation for Glioblastoma in the Era of COVID-19: Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk" 2 and appreciate the opportunity to respond.

For patients with glioblastoma (GBM) who have a very poor performance status (PS) with Karnofsky PS < 50, there is a multitude of treatment options available during the coronavirus disease 2019 (COVID-19) pandemic. Based on prospective data, 34 Gy in 10 fractions, 25 Gy in 5 fractions, temozolomide (TMZ) alone, or best supportive care are potential options, although patients with KPS < 50 (Eastern Cooperative Oncology Group [ECOG] 3-4) were not necessarily well represented among the accrued patients in these trials. 3, 4 We agree with Rathod et al and recognize the immunosuppressive side effects of TMZ, such as neutropenia, which may increase risk of COVID infection or COVID-related severe illness or death. Consistent with other published neuro-oncology guidelines for the COVID era, 5 TMZ is an option for consideration, particularly among those patients with hypermethylation of the O[6]-methylguanine-DNA methyltransferase (MGMT) promoter. Yet the use of TMZ even among patients with MGMT methylation (who are most likely to benefit from TMZ) is cautioned in the context of known TMZ hematologic toxicity. Although TMZ has known hematologic toxicity, there is growing evidence that radiation has also been found to have immunosuppressive effects in GBM through the killing of circulating lymphocytes. 6 Thus, the advantages and limitations of each treatment modality must be carefully weighed, especially during the ongoing COVID-19 crisis.

In conclusion, the integration of prospective triallevel data with clinical context, individualized patient considerations, multidisciplinary discussions, and shared decision-making with patients and their families is paramount to the discussion of the treatment of vulnerable patients with GBM during the COVID-19 pandemic.

In regard to "Radiation for glioblastoma in the era of COVID-19: Patient selection and hypofractionation to maximize benefit and minimize risk

Radiation for glioblastoma in the era of COVID-19: Patient selection and hypofractionation to maximize benefit and minimize risk

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial

International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme

Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas

Lymphopenia, and host immune capacity in glioblastoma: A potentially actionable toxicity associated with reduced efficacy of radiotherapy

Disclosures: The authors report no conflict of interest relative to this work